(Q73919585)

English

Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering?

scientific article published on 01 November 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9388100%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering? (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9388100%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

based on heuristic

inferred from title

coronary artery disease

1 reference

based on heuristic

inferred from title

author name string

P Cullen

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9388100%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

G Assmann

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9388100%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

0 references

publication date

1 November 1997

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9388100%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9388100%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

80

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9388100%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9388100%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1287-1294

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9388100%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Risk factors that attenuate the female coronary disease advantage

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

On lowering lipids in the post-infarction patient

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Plasmapheresis for prevention and regression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Report of the Conference on Low Blood Cholesterol: Mortality Associations

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Carcinogenicity of lipid-lowering drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900667-X

7 January 2021

Identifiers

10.1016/S0002-9149(97)00667-X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9388100%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9388100%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73919585&oldid=1945163280"